We are really excited about the progress we have seen in the EXPLORER-HCM trial, and after the results are published in the first half of 2020, we will quickly begin conversations to seek FDA approval of mavacamten, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
We are really excited about the progress we have seen in the EXPLORER-HCM trial, and after the results are published in the first half of 2020, we will quickly begin conversations to seek FDA approval of mavacamten, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
Transcript
What is the importance of the Cleveland Clinic study assessing mavacamten as an alternative to septal reduction therapy?
We said that for some patients, their only option for getting any type of symptomatic improvement is surgery. This is actually a surgery where the septum is actually debulked—it's an open heart procedure where a piece of the septum is surgically removed, or alternatively, in a cardiac catheterization procedure, alcohol is injected into the sceptile artery to actually induce a targeted myocardial infarction. We think that mavacamten can offer an important alternative for these patients. So, working with the Cleveland Clinic, and other great centers, which focus on being able to provide septal reduction therapy, we're looking forward to being able to start a study where we can show show that mavacamten can prevent the need for surgery in many patients.
What is the overall time frame for mavacamten seeking FDA approval?
We're really excited about the progress that we're seeing in EXPLORER-HCM. We're looking for those results in the first half of 2020. With that, we’ll quickly move to a discussion with the FDA and get ready for filing mavacamten for its first indication. We're looking forward to that quickly there afterwards and then seeking the review with the FDA for approval.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More